Dipeptidyl Peptidase IV Inhibitors Reduce Hepatic Fibrosis and Lipid Accumulation in Rat Intestinal Failure-associated Liver Disease Models

Overview

Journal Pediatr Surg Int

Specialties General Surgery
Pediatrics

Date 2024 Oct 29

PMID 39470835

Authors

Ryo Sueyoshi

Junya Ishii

Susumu Yamada

Marumi Kawakami

Kenji Tanabe

Osamu Segawa

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aimed to investigate the effectiveness of dipeptidyl peptidase IV inhibitors (DPP4-I) against liver damage, especially fibrosis and lipid accumulation, in a rat intestinal failure-associated liver disease (IFALD) model.

Methods: SD rats were divided into two groups: the Control (n = 7; normal saline + IFALD model) and DPP4-I (n = 7; DPP4-I + IFALD model; short bowel syndrome (SBS) + total parenteral nutrition) groups. All rats were euthanized 21 days postoperatively to obtain tissue samples. Liver fibrosis was evaluated by Sirius Red and α-SMA staining. Liver damage was assessed using the steatosis, activity, and fibrosis score. Inflammation cytokines were examined by ELISA.

Results: The survival rate was comparatively different, being 87.5% in the DPP4-I group and 70.0% in the Control group. Two rats of the Control group showed progressive liver fibrosis in the periportal area with fibrous streaks. Further, the mean area percentage of α-SMA immune-positive cells was significantly lower in the DPP4-I group than in the Control group. TGF-β levels were significantly lower in the DPP4-I group than in the Control group.

Conclusion: DPP4-I administration reduced liver fibrosis in IFALD, possibly by inhibiting DPP4-I-induced adipogenesis and suppressing TGF-β. These results may contribute to elucidating the mechanism of IFALD.

References

Duggan C, Jaksic T . Pediatric Intestinal Failure. N Engl J Med. 2017; 377(7):666-675. DOI: 10.1056/NEJMra1602650. View

Lal S, Pironi L, Wanten G, Arends J, Bozzetti F, Cuerda C . Clinical approach to the management of Intestinal Failure Associated Liver Disease (IFALD) in adults: A position paper from the Home Artificial Nutrition and Chronic Intestinal Failure Special Interest Group of ESPEN. Clin Nutr. 2018; 37(6 Pt A):1794-1797. DOI: 10.1016/j.clnu.2018.07.006. View

Shakhsheer B, Warner B . Short Bowel Syndrome. Curr Treat Options Pediatr. 2020; 5(4):494-505. PMC: 7728382. DOI: 10.1007/s40746-019-00179-y. View

Jeppesen P, Sanguinetti E, Buchman A, Howard L, Scolapio J, Ziegler T . Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005; 54(9):1224-31. PMC: 1774653. DOI: 10.1136/gut.2004.061440. View

Chen L, Zhang X, Zhang L, Zheng D . Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease. Diabetes Metab Syndr Obes. 2020; 13:3507-3518. PMC: 7547785. DOI: 10.2147/DMSO.S262284. View

Hattori S, Nomoto K, Suzuki T, Hayashi S . Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Diabetol Metab Syndr. 2021; 13(1):28. PMC: 7945344. DOI: 10.1186/s13098-021-00644-5. View

Sueyoshi R, Furuhashi N, Ishii J, Yamaguchi R, Kawakami M, Tanabe K . Decreased liver damage in rat models of short bowel syndrome through DPP4 inhibition. Pediatr Surg Int. 2022; 39(1):21. DOI: 10.1007/s00383-022-05301-0. View

Lauriti G, Zani A, Aufieri R, Cananzi M, Lelli Chiesa P, Eaton S . Incidence, prevention, and treatment of parenteral nutrition-associated cholestasis and intestinal failure-associated liver disease in infants and children: a systematic review. JPEN J Parenter Enteral Nutr. 2013; 38(1):70-85. DOI: 10.1177/0148607113496280. View

Khalaf R, Sokol R . New Insights Into Intestinal Failure-Associated Liver Disease in Children. Hepatology. 2020; 71(4):1486-1498. PMC: 8245203. DOI: 10.1002/hep.31152. View

10.

El Kasmi K, Anderson A, Devereaux M, Vue P, Zhang W, Setchell K . Phytosterols promote liver injury and Kupffer cell activation in parenteral nutrition-associated liver disease. Sci Transl Med. 2013; 5(206):206ra137. PMC: 4070735. DOI: 10.1126/scitranslmed.3006898. View

11.

Onishi S, Kaji T, Yamada W, Nakame K, Moriguchi T, Sugita K . The administration of ghrelin improved hepatocellular injury following parenteral feeding in a rat model of short bowel syndrome. Pediatr Surg Int. 2016; 32(12):1165-1171. DOI: 10.1007/s00383-016-3975-1. View

12.

Brinkman A, Murali S, Hitt S, Solverson P, Holst J, Ney D . Enteral nutrients potentiate glucagon-like peptide-2 action and reduce dependence on parenteral nutrition in a rat model of human intestinal failure. Am J Physiol Gastrointest Liver Physiol. 2012; 303(5):G610-22. PMC: 3468558. DOI: 10.1152/ajpgi.00184.2012. View

13.

Cavicchi M, Beau P, Crenn P, Degott C, Messing B . Prevalence of liver disease and contributing factors in patients receiving home parenteral nutrition for permanent intestinal failure. Ann Intern Med. 2000; 132(7):525-32. DOI: 10.7326/0003-4819-132-7-200004040-00003. View

14.

Buchman A, Naini B, Spilker B . The Differentiation of Intestinal-Failure-Associated Liver Disease from Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis. Semin Liver Dis. 2017; 37(1):33-44. DOI: 10.1055/s-0036-1597771. View

15.

Quigley E, Marsh M, Shaffer J, Markin R . Hepatobiliary complications of total parenteral nutrition. Gastroenterology. 1993; 104(1):286-301. DOI: 10.1016/0016-5085(93)90864-9. View

16.

Tandra S, Yeh M, Brunt E, Vuppalanchi R, Cummings O, Unalp-Arida A . Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease. J Hepatol. 2010; 55(3):654-659. PMC: 3139780. DOI: 10.1016/j.jhep.2010.11.021. View

17.

Kaji K, Yoshiji H, Ikenaka Y, Noguchi R, Aihara Y, Douhara A . Dipeptidyl peptidase-4 inhibitor attenuates hepatic fibrosis via suppression of activated hepatic stellate cell in rats. J Gastroenterol. 2013; 49(3):481-91. DOI: 10.1007/s00535-013-0783-4. View

18.

Di Dato F, Iorio R, Spagnuolo M . IFALD in children: What's new? A narrative review. Front Nutr. 2022; 9:928371. PMC: 9358220. DOI: 10.3389/fnut.2022.928371. View

19.

Katsuma S, Hirasawa A, Tsujimoto G . Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem Biophys Res Commun. 2005; 329(1):386-90. DOI: 10.1016/j.bbrc.2005.01.139. View

20.

Naimi R, Hvistendahl M, Thomassen L, Johnsen H, Christiansen C, Holst J . Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study. BMJ Open Gastroenterol. 2021; 8(1). PMC: 8117993. DOI: 10.1136/bmjgast-2021-000604. View